Preferred Label : Safety Report;

NCIt related terms : SafetyReportVersion; Safety Reports;

NCIt definition : A report that provides notification of an adverse event, product problem, and/or information that is relevant to either. A report typically includes causal association, management strategies, authorship, sender/receiver organizations, subject of adverse event, or name of product.;

Alternative definition : FDA: Life-threatening, serious and unexpected adverse events as described in 21 CFR 312.32, 600.80 and 314.80 Periodic adverse event report: Post-marketing report required by CFR 600.80 to be submitted quarterly for three (3) years, then annually, upon approval/licensing of vaccine or biologic product.; BRIDG 3.0.3: A report that provides notification of an adverse event, product problem, and/or information that is relevant to either. A report typically includes causal association, management strategies, authorship, sender/receiver organizations, subject of adverse event, or name of product. EXAMPLE(S): An Expedited AE report - a report of a serious and unexpected adverse event that must be submitted within specific timeframes to the sponsor and regulatory agencies.; BRIDG 5.3: A report that provides notification of an adverse event, product problem, and/or information that is relevant to either. A report typically includes causal association, management strategies, authorship, sender/receiver organizations, subject of adverse event, or name of product. EXAMPLE(S): An Expedited AE report - a report of a serious and unexpected adverse event that must be submitted within specific timeframes to the sponsor and regulatory agencies. OTHER NAME(S): NOTE(S):;

Details


Main resources

You can consult :


https://iris.who.int/bitstream/handle/10665/376333/WHO-WHE-EPP-2024.3-fre.pdf
2024
Switzerland
public health guidelines
Montreal Cognitive Assessment Orientation Test
Biological Son
Biological or Textual Reference to Actual Test or Parameter
CDISC ADAS-Cog - Orientation Summary Score
orientation
biology
Clinical Trial Notification of Safety Information
Referral
Biological
Biological Challenge Agent
SARS Coronavirus
laboratory reporting, nos
Biology
biology
Institutional Review Board Independent Ethics Committee Notification of Safety Information Document
SARS-CoV-2
safety
containment of biohazards
Direction
Orientation
Referring
Safety Report
laboratories
COVID-19 Infection
Biological Agent
orientation, nos
research report
COVID-19

---
https://assurance-maladie.ameli.fr/etudes-et-donnees/2024-vedolizumab-ustekinumab-anti-tnf-grossesse-mici
2024
France
scientific and technical information
safety
TNF Gene
Ustekinumab
inflammatory bowel disease, nos
tumor necrosis factor
Institutional Review Board Independent Ethics Committee Notification of Safety Information Document
Physically Feel in Bad Condition
tumor necrosis factors
Safety Report
Clinical Trial Notification of Safety Information
chronic disease, nos
Vedolizumab
research report
vedolizumab
disease
Tumor Necrosis Factor
anti-TNF
Ustekinumab
Chronic Disease
pregnant women
inflammatory bowel diseases
vedolizumab
pregnancy, nos
albumin/globulin ratio
chronic disease
Gravida

---
Nous contacter.
12/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.